Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy

Código QR

Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy

Eric K Chin, David RP Almeida, C Nathaniel Roybal, Philip I Niles, Karen M Gehrs, Elliott H Sohn, H Culver Boldt, Stephen R Russell, James C FolkDepartment of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USAPurpose: To evaluate the effect and tolerance of oral mineralocortic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chin EK, Almeida DRP, Roybal CN, Niles PI, Gehrs KM, Sohn EH, Boldt HC, Russell SR, Folk JC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/355b2c0c1c464815846bbeeb8c857349
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy
por: Róbert Gergely, et al.
Publicado: (2020)

Long-term outcomes in patients undergoing vitrectomy for retinal detachment due to viral retinitis
por: Almeida DRP, et al.
Publicado: (2015)

Comparison of microbiology and visual outcomes of patients undergoing small-gauge and 20-gauge vitrectomy for endophthalmitis
por: Almeida DRP, et al.
Publicado: (2016)

Photodynamic therapy combined with antivascular endothelial growth factor treatment for recalcitrant chronic central serous chorioretinopathy
por: Asahi MG, et al.
Publicado: (2017)

Treatment of central serous chorioretinopathy with topical NSAIDs
por: Bahadorani S, et al.
Publicado: (2019)

Central Serous Chorioretinopathy: Pathogenesis and Management
por: Semeraro F, et al.
Publicado: (2019)

Central serous chorioretinopathy: a pathogenetic model
por: et al, et al.
Publicado: (2011)

Transpupillary thermotherapy for atypical central serous chorioretinopathy
por: Kawamura R, et al.
Publicado: (2012)

Low-dose aspirin as treatment for central serous chorioretinopathy
por: Antonio Caccavale, et al.
Publicado: (2010)

Characteristics of intraretinal deposits in acute central serous chorioretinopathy
por: Plateroti AM, et al.
Publicado: (2014)

Navigated focal laser photocoagulation for central serous chorioretinopathy
por: Chhablani J, et al.
Publicado: (2014)

Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy
por: Mohabati D, et al.
Publicado: (2018)

Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
por: Karim SP, et al.
Publicado: (2013)

Microsecond yellow laser for subfoveal leaks in central serous chorioretinopathy
por: Ambiya V, et al.
Publicado: (2016)

Predicting Central Serous Chorioretinopathy Recurrence Using Machine Learning
por: Fabao Xu, et al.
Publicado: (2021)

Forgotten exogenous corticosteroid as a cause of central serous chorioretinopathy
por: Paul W Hardwig, et al.
Publicado: (2008)

GRADED CRITERIA OF DIAGNOSTICS AND PREDICTION OF CENTRAL SEROUS CHORIORETINOPATHY OUTCOME
por: A. G. Shchuko, et al.
Publicado: (2016)

Features of emotional and personality status of patients with central serous chorioretinopathy
por: A. A. Shchuko, et al.
Publicado: (2016)

In patients suffering from idiopathic central serous chorioretinopathy, anxiety scores are higher than in healthy controls, but do not vary according to sex or repeated central serous chorioretinopathy
por: Bazzazi N, et al.
Publicado: (2015)

Scleral buckle hemorrhagic cyst masquerading as an orbital tumor
por: Almeida DRP, et al.
Publicado: (2015)

New clinical opportunities for mineralocorticoid receptor antagonists: focus on antifibrotic effects
por: Natalia A. Dragomiretskaya, et al.
Publicado: (2021)

Risk of Recurrence and Transition to Chronic Disease in Acute Central Serous Chorioretinopathy
por: Mohabati D, et al.
Publicado: (2020)

Modified Low Power Mode Laser for the Treatment of Central Serous Chorioretinopathy
por: Miura M, et al.
Publicado: (2020)

Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy
por: Abd Elhamid AH
Publicado: (2015)

Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function.
por: Anna Jonsson Holmdahl, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
por: Anna Jonsson Holmdahl, et al.
Publicado: (2021)

Short wavelength automated perimetry and standard automated perimetry in central serous chorioretinopathy
por: Han Peng Zhou, et al.
Publicado: (2020)

Multiple spots of photodynamic therapy for the treatment of severe chronic central serous chorioretinopathy
por: Tsakonas GD, et al.
Publicado: (2012)

Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy
por: Ratanasukon M, et al.
Publicado: (2013)

Evaluation of Psychophysiological and Hormonal Changes in Acute and Chronic Forms of Central Serous Chorioretinopathy
por: A. A. Shchuko, et al.
Publicado: (2019)

Short Axial Length Is Related to Asymmetric Vortex Veins in Central Serous Chorioretinopathy
por: Nobuhiro Terao, MD, PhD, et al.
Publicado: (2021)

Multicolor imaging in central serous chorioretinopathy – a quantitative and qualitative comparison with fundus autofluorescence
por: Vishal Govindahari, et al.
Publicado: (2019)

Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
por: Sanguansak T, et al.
Publicado: (2015)

Clinical features of pachyvessels associated with polypoidal choroidal vasculopathy in chronic central serous chorioretinopathy
por: Te-An Wang, et al.
Publicado: (2021)

Changes of outer retinal microstructures after photodynamic therapy for chronic central serous chorioretinopathy
por: Shimizu K, et al.
Publicado: (2017)

Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapy
por: Fujita K, et al.
Publicado: (2012)

Persistent subretinal fluid due to central serous chorioretinopathy after retinal detachment surgery
por: Moreno-L&oacute;pez M, et al.
Publicado: (2011)

Factors affecting resolution of subretinal fluid after selective retina therapy for central serous chorioretinopathy
por: Akika Kyo, et al.
Publicado: (2021)

Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy
por: Mohabati D, et al.
Publicado: (2018)

Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy
por: Mazzolani F
Publicado: (2012)